The Mifepristone Case and the Legitimacy of the FDA
Gluck A. The Mifepristone Case and the Legitimacy of the FDA. JAMA 2023, 329: 2121-2122. PMID: 37266955, DOI: 10.1001/jama.2023.8712.Peer-Reviewed Original ResearchCost-Free Preventive Care Under the ACA Faces Legal Challenge
Gluck A, Gostin L. Cost-Free Preventive Care Under the ACA Faces Legal Challenge. JAMA 2023, 329: 1733-1734. PMID: 37036869, DOI: 10.1001/jama.2023.6584.Peer-Reviewed Original ResearchTargeting Health-Related Social Risks in the Clinical Setting: New Policy Momentum and Practice Considerations.
Shultz B, Oladele C, Leeds I, Gluck A, Gross C. Targeting Health-Related Social Risks in the Clinical Setting: New Policy Momentum and Practice Considerations. The Journal Of Law, Medicine & Ethics 2023, 51: 777-785. PMID: 38477272, DOI: 10.1017/jme.2024.25.Peer-Reviewed Original ResearchConceptsSocial determinants of healthDeterminants of healthHealth care entitiesHealth inequalitiesSocial determinantsEmergency medicineHealth careCare entitiesAccrediting organizationsHealthClinical practiceField of oncologyClinical settingPolicy momentumSocial risksCareProvidersPracticeInterventionIllnessPractical considerationsAccreditationOncologyFederal governmentClinic